Search

everythinglearnresearchcommunity

for

Search:↓

A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.

Genetic insights can lead to personalized treatments for acne, androgenetic alopecia, and alopecia areata.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Accurate diagnosis and personalized treatment are crucial in dermatopathology.

A PIK3CA mutation in Schwann cells causes severe nerve damage and increased glycolysis, but early treatment can help.

High LH levels cause hair loss by damaging and aging hair follicles.

Jiawei Erzhiwan helps hair growth in androgenetic alopecia by affecting specific cell pathways.

Frontal fibrosing alopecia in men is often misdiagnosed and needs better diagnostic criteria and treatment strategies.

Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.

RIPK1 inhibitors may help prevent alopecia areata by reducing immune cell activity.

Combination pharmacotherapy is generally more effective for treating keloids and hypertrophic scars.

Effective treatment guidelines for frontal fibrosing alopecia are still unclear.

Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.

Brain-made chemicals can control nerve cell function differently in various parts of a mouse's brain, which may help us understand neurological conditions.

Finasteride does not increase the risk of depression or suicide.

Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

Men taking 5-alpha reductase inhibitors for prostate issues may be less likely to experience severe COVID-19, but it doesn't prevent ICU admission or death.

Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.

Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.

The article concludes that understanding Frontal Fibrosing Alopecia (FFA) is crucial for effective treatment, which includes medication like 5α-reductase inhibitors and hydroxychloroquine.

A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.

Intralesional corticosteroids and 5-alpha-reductase inhibitors are the best treatments for frontal fibrosing alopecia.

Sex steroids, especially progesterone, can slow down the growth of mouse melanoma cells.

Men are more at risk for severe COVID-19 due to biological differences, suggesting the need for targeted treatments.

The conclusion is that more hair loss (androgenetic alopecia) is linked to larger prostate size, suggesting hair loss could be an early sign of benign prostatic hyperplasia.

Polygenic risk scores can predict the risk and outcomes of benign prostatic hyperplasia.

Gender-affirming therapy can cause skin issues like acne and hair loss in transgender adolescents, and more research is needed on its dermatological effects.